drugset / Trial / NCT05082584

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents

NCT05082584

Phase 3 Withdrawn Akebia Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

This study will assess the safety and efficacy of once daily dosing of vadadustat for the treatment of pediatric participants with anemia of chronic kidney disease (CKD) naive to erythropoiesis-stimulating agent (ESA) treatment.

Timeline

Start
2025-01
Primary completion
2026-07
Completion
2026-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Vadadustat Small molecule Oral